NeoPharm CO., LTD. announced that it expects to receive KRW 31.970667276 billion in funding
May 23, 2019
Share
NeoPharm CO., LTD. (KOSDAQ:A092730) announced a private placement of 746,124 common shares at a price of KRW 42,849 per share for gross proceeds of KRW 31,970,667,276 on May 24, 2019. The shares have a face value of KRW 500 per share. The shares will be issued at a discount and through third party allotment. The transaction was approved by the board of directors.
NeoPharm Co., Ltd. is a Korea-based company engaged in the manufacture of cosmetics. The Company produces its products under brand names of ATOPALM, including daily care, intensive care, special care and baby care products; Derma:B, including foam cleansers, oil cleansers, toners, emulsions, creams, facial masks, blemish base (BB) creams, sun protectors, white watering serums, anti-aging eye creams and others; ZEROID, including creams and lotions for recovering damaged skin barriers and hypollalergenic foaming cleansers for atopy and sensitive skins, and others. It also engages in the original equipment manufacturing (OEM) of skin drugs.